CDK6 and metabolic disease: Notably, a marked increase in lipogenesis and lipid accumulation was observed in the WAT of mouse models with impaired CDK6 activity, further corroborating the potential of CDK4/6 inhibition as a therapeutic strategy for obesity-related metabolic disorders [181].